Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Opdivo (nivolumab)
i
Other names:
ONO-4538, BMS-936558, MDX-1106, NSC 748726, BMS936558, ono-0123, GTPL7335, GTPL 7335
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(560)
News
Twitter
Trials
Company:
BMS, Ono Pharma
Drug class:
PD1 inhibitor
Related drugs:
‹
pembrolizumab (673)
sintilimab (100)
toripalimab (84)
camrelizumab (80)
tislelizumab (72)
dostarlimab-gxly (33)
cemiplimab (28)
AB122 (16)
ABBV-181 (13)
PDR001 (13)
pucotenlimab (10)
AGEN2034 (9)
serplulimab (6)
retifanlimab-dlwr (6)
penpulimab (5)
cadonilimab (5)
JNJ-63723283 (5)
PF-06801591 (5)
MGD013 (5)
nivolumab/relatlimab (4)
geptanolimab (3)
PSB205 (3)
AK112 (3)
MEDI0680 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
AI-061 (0)
AK129 (0)
AMP-224 (0)
ASKG915 (0)
AWT020 (0)
AZD7789 (0)
Anti LAG3/PD-1 BsAb (0)
(0)
BAT1306 (0)
BAT1308 (0)
BC008-1A (0)
(0)
BSI-507 (0)
BSI-508 (0)
BZD1901 (0)
CART-BCMA&PD-1 (0)
CB213 (0)
CCX4503 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
CTLA-4/PD-1 antibodies expressing mesoCAR-T (0)
CTX-8371 (0)
CX-188 (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
EX104 (0)
enlonstobart (0)
(0)
prolgolimab (0)
GC201 TIL (0)
GNR-051 (0)
GNUV201 (0)
GNUV205 (0)
HX-009 (0)
IAP0971 (0)
IBI319 (0)
IBI321 (0)
IBI363 (0)
IKT-202 (0)
IMM1802 (0)
INCA32459 (0)
INCA33890 (0)
INTASYL sd RNAi dual-targeting PD-1/CTLA-4 (0)
JS201 (0)
JS207 (0)
LB1410 (0)
LBL-015 (0)
LNL005 (0)
LQ008 (0)
LVGN3616 (0)
LZM009 (0)
MASCT-I (0)
MAX-10129 (0)
MAX-5 (0)
MAX-6 (0)
MAX-7 (0)
MB12 (0)
MB201 (0)
MBS309 (0)
MCLA-134 (0)
MDG1015 (0)
MDNA223 (0)
MVR-C5252 (0)
MVR-T7011 (0)
MVR-T7012 (0)
MVR-T7013 (0)
MW11 (0)
NY-ESO-1 TCR-T cell therapy (0)
OCX-410 (0)
OGB23501 (0)
ONCR-177 (0)
ONCR-719 (0)
ONO-4685 (0)
OSE-279 (0)
nivolumab subcutaneous (0)
PD-1 knockout engineered T cells (0)
PD-1 knockout engineered T cells (0)
PD-1 mAb (0)
PD1 x TGFβR2 XmAb therapeutic (0)
PD1/LILRB1 BiTE (0)
PE0105 (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PH-762 TME (0)
PRGN-3007 (0)
QL1604 (0)
RB-240 (0)
RB-340 (0)
RB-340-2 (0)
REMD-511 (0)
REMD-532 (0)
REMD-813 (0)
SAR445877 (0)
SAUG 1 (0)
SAUG2 (0)
SHR-1901 (0)
SHS-010 (0)
SI-B003 (0)
SL-279252 (0)
SSGJ-705 (0)
SSGJ-706 (0)
STI-A1110 (0)
STM418 (0)
STW204 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TC-E202 (0)
TST005 (0)
TY 101 (0)
Undisclosed next gen MSLN UltraCAR-T (0)
WTX212 (0)
(0)
YH008 (0)
ZG005 (0)
YBL-006 (0)
dual anti-MUC16 CAR T-cell therapy/PD-1 checkpoint inhibitor (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
RG7769 (0)
MGD019 (0)
BMS-986213/rHuPH20 (0)
MK-3475 SC (0)
MK-3475A (0)
CT-011 (0)
BCD-217 (0)
MK-1308A (0)
rHSV-1-APD1 (0)
IBI318 (0)
AZD2936 (0)
F520 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
pembrolizumab (673)
sintilimab (100)
toripalimab (84)
camrelizumab (80)
tislelizumab (72)
dostarlimab-gxly (33)
cemiplimab (28)
AB122 (16)
ABBV-181 (13)
PDR001 (13)
pucotenlimab (10)
AGEN2034 (9)
serplulimab (6)
retifanlimab-dlwr (6)
penpulimab (5)
cadonilimab (5)
JNJ-63723283 (5)
PF-06801591 (5)
MGD013 (5)
nivolumab/relatlimab (4)
geptanolimab (3)
PSB205 (3)
AK112 (3)
MEDI0680 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
AI-061 (0)
AK129 (0)
AMP-224 (0)
ASKG915 (0)
AWT020 (0)
AZD7789 (0)
Anti LAG3/PD-1 BsAb (0)
(0)
BAT1306 (0)
BAT1308 (0)
BC008-1A (0)
(0)
BSI-507 (0)
BSI-508 (0)
BZD1901 (0)
CART-BCMA&PD-1 (0)
CB213 (0)
CCX4503 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
CTLA-4/PD-1 antibodies expressing mesoCAR-T (0)
CTX-8371 (0)
CX-188 (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
EX104 (0)
enlonstobart (0)
(0)
prolgolimab (0)
GC201 TIL (0)
GNR-051 (0)
GNUV201 (0)
GNUV205 (0)
HX-009 (0)
IAP0971 (0)
IBI319 (0)
IBI321 (0)
IBI363 (0)
IKT-202 (0)
IMM1802 (0)
INCA32459 (0)
INCA33890 (0)
INTASYL sd RNAi dual-targeting PD-1/CTLA-4 (0)
JS201 (0)
JS207 (0)
LB1410 (0)
LBL-015 (0)
LNL005 (0)
LQ008 (0)
LVGN3616 (0)
LZM009 (0)
MASCT-I (0)
MAX-10129 (0)
MAX-5 (0)
MAX-6 (0)
MAX-7 (0)
MB12 (0)
MB201 (0)
MBS309 (0)
MCLA-134 (0)
MDG1015 (0)
MDNA223 (0)
MVR-C5252 (0)
MVR-T7011 (0)
MVR-T7012 (0)
MVR-T7013 (0)
MW11 (0)
NY-ESO-1 TCR-T cell therapy (0)
OCX-410 (0)
OGB23501 (0)
ONCR-177 (0)
ONCR-719 (0)
ONO-4685 (0)
OSE-279 (0)
nivolumab subcutaneous (0)
PD-1 knockout engineered T cells (0)
PD-1 knockout engineered T cells (0)
PD-1 mAb (0)
PD1 x TGFβR2 XmAb therapeutic (0)
PD1/LILRB1 BiTE (0)
PE0105 (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PH-762 TME (0)
PRGN-3007 (0)
QL1604 (0)
RB-240 (0)
RB-340 (0)
RB-340-2 (0)
REMD-511 (0)
REMD-532 (0)
REMD-813 (0)
SAR445877 (0)
SAUG 1 (0)
SAUG2 (0)
SHR-1901 (0)
SHS-010 (0)
SI-B003 (0)
SL-279252 (0)
SSGJ-705 (0)
SSGJ-706 (0)
STI-A1110 (0)
STM418 (0)
STW204 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TC-E202 (0)
TST005 (0)
TY 101 (0)
Undisclosed next gen MSLN UltraCAR-T (0)
WTX212 (0)
(0)
YH008 (0)
ZG005 (0)
YBL-006 (0)
dual anti-MUC16 CAR T-cell therapy/PD-1 checkpoint inhibitor (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
RG7769 (0)
MGD019 (0)
BMS-986213/rHuPH20 (0)
MK-3475 SC (0)
MK-3475A (0)
CT-011 (0)
BCD-217 (0)
MK-1308A (0)
rHSV-1-APD1 (0)
IBI318 (0)
AZD2936 (0)
F520 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
›
Associations
(560)
News
Twitter
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
TMB-H
Melanoma
TMB-H
Melanoma
nivolumab
Sensitive: B - Late Trials
ASCO 2023 - 1 week (New B)
nivolumab
Sensitive
:
B
ASCO 2023 - 1wk
nivolumab
Sensitive: B - Late Trials
ASCO 2023 - 1 week
nivolumab
Sensitive
:
B
ASCO 2023 - 1 week - (New B)
IL6 elevation
Melanoma
IL6 elevation
Melanoma
nivolumab + ipilimumab
Resistant: B - Late Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Resistant
:
B
ASCO 2023 - 1wk
nivolumab + ipilimumab
Resistant: B - Late Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Resistant
:
B
ASCO 2023 - 1 week - (New C3)
High IFNG gene signature
Melanoma
High IFNG gene signature
Melanoma
nivolumab
Sensitive: B - Late Trials
ASCO 2023 - 1 week (New B)
nivolumab
Sensitive
:
B
ASCO 2023 - 1wk
nivolumab
Sensitive: B - Late Trials
ASCO 2023 - 1 week
nivolumab
Sensitive
:
B
ASCO 2023 - 1 week - (New B)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
A1
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
A1
ASCO 2023 - 1 week - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab
Sensitive: B - Late Trials
Bristol-Myers Squibb Press Release - 1 week (New B)
nivolumab
Sensitive
:
B
Bristol-Myers Squibb Press Release - 1wk
nivolumab
Sensitive: B - Late Trials
Bristol-Myers Squibb Press Release - 1 week
nivolumab
Sensitive
:
B
Bristol-Myers Squibb Press Release - 1 week - (New B)
BRAF mutation
Melanoma
BRAF mutation
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
B
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: B - Late Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
B
ASCO 2023 - 1 week - (New C3)
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
nivolumab
Sensitive: C1 - Off-label
ASCO 2023 - 1 week (New C3)
nivolumab
Sensitive
:
C1
ASCO 2023 - 1wk
nivolumab
Sensitive: C1 - Off-label
ASCO 2023 - 1 week
nivolumab
Sensitive
:
C1
ASCO 2023 - 1 week - (New C3)
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
nivolumab
Sensitive: C1 - Off-label
ASCO 2023 - 1 week (New C3)
nivolumab
Sensitive
:
C1
ASCO 2023 - 1wk
nivolumab
Sensitive: C1 - Off-label
ASCO 2023 - 1 week
nivolumab
Sensitive
:
C1
ASCO 2023 - 1 week - (New C3)
PD-L1 expression
Hepatocellular Cancer
PD-L1 expression
Hepatocellular Cancer
nivolumab
Sensitive: C1 - Off-label
ASCO 2023 - 1 week (New C3)
nivolumab
Sensitive
:
C1
ASCO 2023 - 1wk
nivolumab
Sensitive: C1 - Off-label
ASCO 2023 - 1 week
nivolumab
Sensitive
:
C1
ASCO 2023 - 1 week - (New C3)
IDH2 mutation + TMB-L
Glioma
IDH2 mutation + TMB-L
Glioma
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
IDH1 mutation + TMB-L
Glioma
IDH1 mutation + TMB-L
Glioma
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
PMS2 mutation + MLH1 mutation
Gastric Cancer
PMS2 mutation + MLH1 mutation
Gastric Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
PMS2 mutation + MLH1 mutation
Colorectal Cancer
PMS2 mutation + MLH1 mutation
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
HER-2 expression
Solid Tumor
HER-2 expression
Solid Tumor
nivolumab + BDC-1001
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab + BDC-1001
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab + BDC-1001
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab + BDC-1001
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
MSH2 deletion + MSH6 deletion
Rectal Cancer
MSH2 deletion + MSH6 deletion
Rectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
MLH1 deletion+ PMS2 deletion
Rectal Cancer
MLH1 deletion+ PMS2 deletion
Rectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
MSH2 mutation
Rectal Cancer
MSH2 mutation
Rectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
MSH6 mutation
Rectal Cancer
MSH6 mutation
Rectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab + ipilimumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
KRAS wild-type
Non Small Cell Lung Cancer
KRAS wild-type
Non Small Cell Lung Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
CTNNB1 mutation
Hepatocellular Cancer
CTNNB1 mutation
Hepatocellular Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab
Sensitive
:
C3
ASCO 2023 - 1wk
nivolumab
Sensitive: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab
Sensitive
:
C3
ASCO 2023 - 1 week - (New C3)
TP53 mutation
Hepatocellular Cancer
TP53 mutation
Hepatocellular Cancer
nivolumab
Resistant: C3 – Early Trials
ASCO 2023 - 1 week (New C3)
nivolumab
Resistant
:
C3
ASCO 2023 - 1wk
nivolumab
Resistant: C3 – Early Trials
ASCO 2023 - 1 week
nivolumab
Resistant
:
C3
ASCO 2023 - 1 week - (New C3)
KDM1A expression
Small Cell Lung Cancer
KDM1A expression
Small Cell Lung Cancer
nivolumab + ipilimumab
Resistant: C3 – Early Trials
J Thorac Oncol - 2 weeks (New C3)
nivolumab + ipilimumab
Resistant
:
C3
J Thorac Oncol - 2wk
nivolumab + ipilimumab
Resistant: C3 – Early Trials
J Thorac Oncol - 2 weeks
nivolumab + ipilimumab
Resistant
:
C3
J Thorac Oncol - 2 weeks - (New C3)
KDM1A expression
Small Cell Lung Cancer
KDM1A expression
Small Cell Lung Cancer
nivolumab
Resistant: C3 – Early Trials
J Thorac Oncol - 2 weeks (New C3)
nivolumab
Resistant
:
C3
J Thorac Oncol - 2wk
nivolumab
Resistant: C3 – Early Trials
J Thorac Oncol - 2 weeks
nivolumab
Resistant
:
C3
J Thorac Oncol - 2 weeks - (New C3)
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + ipilimumab + cabozantinib tablet
Sensitive: B - Late Trials
N Engl J Med - 3 weeks (New B)
nivolumab + ipilimumab + cabozantinib tablet
Sensitive
:
B
N Engl J Med - 3wk
nivolumab + ipilimumab + cabozantinib tablet
Sensitive: B - Late Trials
N Engl J Med - 3 weeks
nivolumab + ipilimumab + cabozantinib tablet
Sensitive
:
B
N Engl J Med - 3 weeks - (New B)
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastric Cancer
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
LDH elevation
Melanoma
LDH elevation
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600 wild-type
Melanoma
BRAF V600 wild-type
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
EGFR wild-type
Non Small Cell Lung Cancer
EGFR wild-type
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login